Detalles de la búsqueda
1.
In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1.
Drug Metab Dispos
; 45(2): 137-144, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27895114
2.
Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13) C8 ]-evacetrapib as a tracer.
J Labelled Comp Radiopharm
; 59(6): 238-44, 2016 05 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-26639670
3.
The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Drug Metab Dispos
; 40(10): 1945-52, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22789530
4.
Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).
J Pharm Sci
; 104(1): 207-14, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25382826
5.
Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants.
J Clin Pharmacol
; 52(6): 904-13, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21724950
6.
The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats, and monkeys.
Drug Metab Dispos
; 35(1): 51-61, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17012539
Resultados
1 -
6
de 6
1
Próxima >
>>